Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - Ivonescimab (依沃西单抗) demonstrated significant therapeutic benefits in multiple clinical trials, particularly in the HARMONi-2 study where it outperformed pembrolizumab (帕博利珠单抗), showcasing its potential as a global blockbuster [1] - The overseas expansion of Ivonescimab is expected to enhance its revenue peak and company valuation [1] - The company's mature pipeline, including cadonilimab (卡度尼利单抗) and inusirumab (伊努西单抗), is progressing steadily towards commercialization, with new indications and market potential [4] Clinical Results - In the HARMONi-2 study, Ivonescimab showed a significant PFS advantage over pembrolizumab (11.14 vs 5.82 months, HR=0.51) and demonstrated excellent safety with low rates of TRAE-related discontinuation and mortality (1.5% and 0.5%) [2] - Ivonescimab also showed promising efficacy in NSCLC perioperative treatment, head and neck squamous cell carcinoma, colorectal cancer, and TNBC in Phase II trials [2] Overseas Expansion - Ivonescimab's overseas Phase III trials, HARMONi and HARMONi-3, are progressing, with HARMONi-3 expanding its target population to include both squamous and non-squamous NSCLC [3] - The HARMONi-7 study targeting PD-L1 strong-positive NSCLC patients is set to begin in early 2025, further enhancing Ivonescimab's global potential [3] Other Pipelines - Cadonilimab has seen new indications approved and has been included in the national medical insurance, boosting its commercialization potential [4] - Inusirumab, a PCSK9 monoclonal antibody, was approved in September, and other non-oncology drugs are expected to be launched within the next three years [4] Market Differentiation - The report differs from market consensus by expressing strong confidence in the company's overseas potential, citing the robust data from the HARMONi-2 study and the likelihood of replicating domestic success in international markets [5] Financial Forecasts and Valuation - Revenue forecasts for 2024/2025/2026 have been revised downward to 2.312/3.342/5.409 billion RMB (down 13.0/20.8/14.0% from previous estimates) due to national negotiations and the approval pace of non-oncology drugs [6] - The DCF terminal value has been increased from 36 billion to 65.2 billion RMB, leading to a target market cap of 84.5 billion RMB and a target price of 100.45 HKD [6] Industry Insights - The report highlights the potential of IO (immuno-oncology) combined with anti-angiogenesis therapies, noting that while some combinations have shown promise, others have failed due to toxicity and efficacy issues [27][28] - The LEAP series of studies, which explored the combination of pembrolizumab and lenvatinib, showed mixed results, with some studies achieving positive outcomes while others failed to meet OS endpoints [29][30][31]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company is expected to benefit from rising aluminum product prices, with a projected net profit growth of 95% for the fiscal year 2024 compared to the previous year [6] - The increase in alumina prices and stable electrolytic aluminum prices are the main drivers for the significant improvement in the company's performance [6] - The company has a large-scale alumina production capacity, which supports its ongoing performance growth [6] Financial Performance Summary - The average price of alumina in Shandong reached 5,720.00 CNY/ton as of December 17, 2024, with an annual average of 3,963.50 CNY/ton, reflecting a year-on-year increase of 36.5% [6] - The average price of electrolytic aluminum was 19,750.00 CNY/ton as of December 18, 2024, with an annual average of 19,927.25 CNY/ton, showing a year-on-year increase of approximately 6.6% [6] - The company's net profit for 2024-2026 is projected to be 229 billion CNY, 256 billion CNY, and 286 billion CNY respectively [7] Market and Operational Insights - The alumina price is expected to remain strong, potentially driving industry capacity to continue being released in 2025 [7] - The operating rate of electrolytic aluminum in Yunnan has remained high, with a capacity utilization rate of 99.32% in June 2024 [7] - The company is actively expanding its green aluminum production, which is anticipated to provide a competitive advantage due to lower carbon emissions compared to traditional methods [7]

证 券 研 究 报 告 请务必阅读免责条款 | --- | --- | |----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report gives a "Buy" rating for the company, indicating a potential upside of over 20% relative to the market benchmark within the next six months [4][119][136]. Core Insights - The company is positioned as a quality leader in the real estate sector, focusing on core urban areas, with a strong financial structure and declining financing costs [3][44][119]. - The company has shown resilience in sales rankings, achieving significant growth in a challenging market environment, with a focus on high-quality projects and efficient turnover [2][65][75][119]. - The report highlights the company's robust land reserves and its leading position in the construction management sector, which supports future profitability [3][88][98][119]. Summary by Sections 1. Company Overview - Established in 1995, the company has become a leading benchmark for quality in real estate development in China, with total assets exceeding 530 billion RMB and net assets over 100 billion RMB [14][16]. - The company has a stable shareholding structure, with major shareholders including state-owned enterprises, which provide advantages in land acquisition and financing [16][19]. 2. Financial Performance - In 2023, the company achieved revenue of 131.4 billion RMB, a year-on-year increase of 3.3%, with a net profit of 3.09 billion RMB, up 19.6% [2][3][23]. - The company maintains a healthy financial structure, with a debt-to-asset ratio of 69.2% and a net asset-to-debt ratio of 67.2% as of mid-2024 [3][31]. 3. Sales and Market Position - The company has focused on core high-tier cities, with over 79% of its saleable value located in first and second-tier cities as of the first half of 2024 [2][53]. - The average selling price of self-developed projects reached 28,334 RMB/m² in 2023, surpassing the average in core cities [65][70]. 4. Construction Management Business - The company’s subsidiary, Green City Management, is a leader in the construction management sector, with a market share exceeding 20% for eight consecutive years [88][90]. - The management business has shown strong revenue growth, with 2023 revenues of 3.3 billion RMB, reflecting a compound annual growth rate (CAGR) of 10.4% from 2019 to 2023 [90][93]. 5. Profitability Forecast - The company is expected to achieve revenue growth of 135.2 billion RMB in 2024, with net profit projected at 2.77 billion RMB, reflecting a price-to-earnings (P/E) ratio of 7.9 [3][112][119]. - The report anticipates a gradual recovery in the real estate market, positioning the company to capitalize on favorable policies and market conditions [119].

Investment Rating - The report maintains a "Buy" rating for the company Giant Bio (02367.HK) [2][4]. Core Insights - The National Medical Products Administration approved Giant Bio's bone repair materials as a Class III medical device, aligning with the previously expected timeline in the prospectus [3]. - The market for collagen-based biomedical materials has grown from 1 billion RMB in 2017 to 3.2 billion RMB in 2021, with a compound annual growth rate (CAGR) of 33.5%, projected to reach 19.9 billion RMB by 2027, with a CAGR of 35.1% from 2022 to 2027 [3]. - The report highlights the potential for hydroxyapatite in the aesthetic medicine sector, noting its advantages in bone defect filling and soft tissue injection, with a longer-lasting effect compared to traditional fillers [3]. - The company has adjusted its profit forecast upwards, expecting net profits of 2.09 billion RMB, 2.55 billion RMB, and 3.06 billion RMB for 2024-2026, representing year-on-year growth of 43%, 22%, and 20% respectively [4]. Summary by Sections Company Overview - Giant Bio's bone repair materials are designed for dental and alveolar bone defects, utilizing hydroxyapatite particles and macromolecular polysaccharides for effective bone regeneration [3]. Market Analysis - The report discusses the competitive landscape, noting that other companies like Aojing Medical Technology and Tianjin Sain Bio have also received approvals for similar composite bone repair materials [3]. - The aesthetic medicine market for hydroxyapatite is still developing, with no approved Class III products currently available in China, indicating potential growth opportunities [3]. Financial Projections - The report projects revenue growth from 2.36 billion RMB in 2022 to 5.36 billion RMB in 2024, with a growth rate of 52.16% [4]. - The expected return on equity (ROE) is projected to decline from 35.36% in 2022 to 25.20% by 2026, reflecting a strong but decreasing profitability trend [4].

Investment Rating - The report initiates coverage on Green Valley Pharmaceutical (2186 HK) with a "Buy" rating and a target price of HKD 2.90 [3][5] Core Views - Green Valley Pharmaceutical is a well-established pharmaceutical company with a broad sales network covering over 21,000 hospitals in China and 80 countries globally [1] - The company has a diversified product portfolio in oncology, cardiovascular, central nervous system (CNS), and digestive/metabolic fields, with several new drugs expected to be approved by 2025 [1] - The CNS business is expected to grow steadily, driven by strong demand for key products like Seroquel (思瑞康) and Rivastigmine Patch (利斯的明贴剂), with a projected 2023-26E CAGR of 13.2% [2] - The oncology business is expected to recover growth from 2025, supported by new products like Botuowei (百拓维) and Zanbiji (赞必佳) [2] - The cardiovascular business is expected to rebound in the second half of 2024, with a projected 2025-26E CAGR of 5.7% [2] - The digestive/metabolic business is expected to resume growth from 2025, driven by the potential approval of new drugs like Dulaglutide (度拉糖肽) and Aflibercept (阿柏西普) [2] Financial Performance - The company's revenue is expected to grow at a 2023-26E CAGR of 7.2%, with net profit projected to increase by 50.9% in 2024E, followed by 4.6% and 6.5% in 2025E and 2026E, respectively [5] - The oncology segment accounted for 31.0% of total revenue in H1 2024, followed by CNS (29.8%), cardiovascular (27.7%), and digestive/metabolic (7.1%) [17] Product Pipeline and Market Potential - **CNS Products**: Seroquel (思瑞康) is expected to maintain stable sales, while Rivastigmine Patch (利斯的明贴剂) and Ruoxinlin (若欣林) are expected to drive growth with 2023-26E CAGRs of 28.1% and 60.8%, respectively [2][28] - **Oncology Products**: Lipusu (力朴素) is expected to see a moderate recovery in sales from H2 2024, while Botuowei (百拓维) and Zanbiji (赞必佳) are expected to contribute significantly to growth from 2025 [2][44][48] - **Cardiovascular Products**: Xuezhikang (血脂康) is expected to recover sales in H2 2024, while Oukai (欧开) is projected to grow at a 2023-26E CAGR of 23.2% [56][57] - **Digestive/Metabolic Products**: The segment is expected to resume growth from 2025, driven by the potential approval of Dulaglutide (度拉糖肽) and Aflibercept (阿柏西普) [2][60] Valuation and Market Position - The company is currently undervalued compared to industry peers, with a target price of HKD 2.90 based on a 12.0x 2025E PER [5] - Green Valley Pharmaceutical has a strong market position in China, with a broad product portfolio and extensive sales network [1][17]

Investment Rating - The report assigns a "Buy" rating for the company, MAOGEPING [1]. Core Insights - MAOGEPING is a leading domestic high-end beauty brand with a strong financial performance, achieving a revenue of 2.89 billion yuan and a net profit of 660 million yuan in 2023, with a compound annual growth rate (CAGR) exceeding 35% over three years [4][21]. - The brand leverages the founder's reputation, experiential marketing, and high product quality to create a competitive moat, with over 80% of revenue coming from loyal members [4][30]. - The company is expected to maintain strong growth driven by product expansion and channel development, with projected net profits of 910 million yuan, 1.2 billion yuan, and 1.54 billion yuan from 2024 to 2026 [4][145]. Company Overview - MAOGEPING was established in 2000 and is known for its high-end positioning in the beauty market, focusing on both makeup and skincare products [4][10]. - The company has a concentrated ownership structure, with the founder and family holding a significant portion of shares, ensuring stable management [12][16]. Financial Analysis - The company has maintained a high gross margin of approximately 84.8% and a net profit margin of around 23% in 2023, reflecting its strong pricing power and operational efficiency [21][27]. - Revenue and net profit for the first half of 2024 are projected to grow by 41% year-on-year, indicating robust growth momentum [21][145]. Business Analysis - The product mix is heavily weighted towards makeup, with skincare products increasing to 40% of total revenue in 2023, showcasing a successful diversification strategy [30][31]. - The company has a dual-channel strategy, with both offline counters and online sales contributing to its growth, and online sales are expected to continue rising [49][51]. Growth Drivers - The company plans to expand its offline presence by opening approximately 30 new counters annually, while also enhancing its online penetration through platforms like Tmall and Douyin [4][120]. - MAOGEPING aims to introduce new products across various categories, including color cosmetics and skincare, to capture a larger market share [4][137]. Market Analysis - The beauty industry, particularly the makeup segment, is experiencing high growth potential, with domestic brands gaining market share against international competitors [70][80]. - The report highlights the increasing consumer demand for high-end beauty products, driven by changing consumer preferences and a growing middle class [70][78]. Membership and Loyalty - The company has implemented a tiered membership system that enhances customer loyalty, with high repurchase rates among premium members [108][116]. - The loyalty program has contributed significantly to revenue, with premium members accounting for over 80% of total sales [4][116]. Future Outlook - MAOGEPING is exploring international expansion opportunities, aiming to establish a presence in overseas markets while maintaining its high-end brand image [140][141]. - The company is also focusing on product innovation and marketing strategies to enhance brand visibility and consumer engagement [4][137].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 73.96 [8][9]. Core Insights - The company has received its first Class III medical device registration certificate for bone repair materials, indicating promising prospects [1]. - Another Class III medical device, "Injectable Recombinant Collagen Filler" for neck wrinkles, has entered a priority approval channel, potentially shortening its market launch time [1][3]. - The company is expected to receive approval for its eye wrinkle filler product in Q1 2025, which could significantly enhance its performance in the aesthetic medicine sector [1]. - Recent progress in the aesthetic medicine field alleviates market concerns regarding the approval timeline for the company's products, showcasing its R&D capabilities [1]. - The company’s revenue growth is projected to be robust, with expected net profits of RMB 1.998 billion, RMB 2.510 billion, and RMB 3.078 billion for 2024, 2025, and 2026 respectively [5][14]. Summary by Sections Medical Device Approvals - The company has obtained a Class III medical device registration certificate for bone repair materials, targeting dental and jawbone defects, with a market size of approximately RMB 2.67 billion for oral repair membranes and RMB 6.68 billion for bone powder in China [2]. - The injectable collagen filler for neck wrinkles is included in the national key R&D plan for medical devices, qualifying for expedited approval [3]. Financial Performance - The company’s revenue is projected to grow from RMB 2.364 billion in 2022 to RMB 8.385 billion in 2026, with a compound annual growth rate (CAGR) of 25.64% [7][14]. - The net profit is expected to increase from RMB 1.002 billion in 2022 to RMB 3.078 billion in 2026, reflecting a strong growth trajectory [7][14]. - The company maintains a favorable valuation with a projected PE ratio of 28 times for 2025, indicating significant potential for earnings growth [5][12]. Market Position - The company has demonstrated strong growth momentum, with notable GMV increases in its product lines, such as a 69% year-on-year increase for its product "可复美" and a 172% increase for "可丽金" on Douyin [4]. - The company’s aesthetic medicine products, if approved, are expected to contribute significantly to revenue growth, similar to competitors like 锦波生物 and 爱美客 [1][4].

Investment Rating - The report maintains an "Accumulate" rating for the company, with a target price of 2.83 HKD [1]. Core Viewpoints - The company is expected to benefit from consumer stimulus policies, focusing on non-essential consumption [1]. - The company has faced challenges with offline traffic decline but is expanding its online platforms and utilizing new customer acquisition methods [1]. - The report highlights the importance of deepening user engagement through personalized marketing strategies, which have resulted in a stable contribution of 60-70% from repeat members [1]. - The company is diversifying its product offerings and expanding brand partnerships to capture growth in emerging sports segments [1]. - The earnings forecast for FY25-27 is maintained, with projected revenues of 26.5 billion RMB, 28.5 billion RMB, and 29.9 billion RMB, and net profits of 1.39 billion RMB, 1.67 billion RMB, and 1.92 billion RMB respectively [1]. Summary by Relevant Sections Investment Rating - The company is rated "Accumulate" with a current price of 2.83 HKD and a target price set [1]. Business Performance - The company reported a decline in retail and wholesale sales, with a 2.1% decrease in gross sales area and a 4.4% year-on-year decline [1]. - New customer acquisition strategies include the use of mini-programs and partnerships with platforms like Douyin and Meituan [1]. User Engagement - The company is enhancing user experience through tailored product recommendations and marketing strategies, leading to increased user loyalty [1]. - High-value members contribute nearly 40% of total sales despite being a small percentage of total members [1]. Product Diversification - The company is expanding its brand collaboration matrix and entering new sports categories, including partnerships with HOKA ONE ONE and KAILAS [1]. - The company is also collaborating with Fanatics to expand the commercialization of sports IP in Greater China [1]. Financial Forecast - The report maintains the earnings forecast with projected revenues and net profits for FY25-27, along with EPS estimates of 0.22 RMB, 0.26 RMB, and 0.30 RMB respectively [1].

Investment Rating - The report maintains a "Buy" rating for Smoore International with a target price of HKD 13.35, based on a 2025 PE of 48x [1] Core Investment Thesis - Smoore International has experienced a "double whammy" since 2021 due to regulatory headwinds in China and illegal product competition overseas, leading to declining EPS and profitability [1][5] - The company's core advantages remain strong, including leading R&D capabilities, deep customer relationships, and PMTA-approved products in the US [1][6] - Regulatory headwinds in the US and Europe are expected to ease, benefiting Smoore's pod and open-system vape businesses [1][9] - The launch of HNB products by major customers like BAT could create a second growth curve for Smoore [1][13] - Smoore's platform-based advantages in vaporization technology are expected to open new growth opportunities in medical and beauty vaporization [1][14] Market Opportunities US Market - The US illegal vape market accounts for over 70% of the market share, but regulatory crackdowns and potential relaxation of flavor restrictions could drive growth in the legal pod market [1][11] - The mid-term market size for legal pod systems in the US is expected to grow by 63%-299% compared to 2023 levels [1] - FDA has approved menthol-flavored vapes for the first time, signaling a potential easing of flavor restrictions [126] European Market - European countries are gradually implementing bans on disposable vapes, which could benefit Smoore's pod and open-system products [1][12] - The mid-term market size for pod systems in Europe is expected to grow by 42%-60%, while open-system products could grow by 52%-75% compared to 2023 levels [1] HNB Market - The global HNB market reached $34.1 billion in 2023, with a CAGR of 23.1% from 2018-2023 [1][13] - Smoore's major customer BAT is launching a breakthrough HNB product, Glo Hilo, in 2025, which could drive significant growth [1][13][159] Financial Performance - Revenue declined by 11.71% in 2022 and 8.04% in 2023, but is expected to grow by 7.8% in 2024 and 21.21% in 2026 [3] - Net profit attributable to shareholders dropped by 52.52% in 2022 and 34.47% in 2023, but is projected to grow by 43.02% in 2026 [3] - EPS is forecasted to be RMB 0.22, 0.26, and 0.37 for 2024-2026, respectively [1] R&D and Innovation - Smoore has maintained high R&D investment, with R&D expenses reaching RMB 1.483 billion in 2023, a 435% increase from 2019 [92] - The company has accumulated 7,695 patents globally, including 3,867 invention patents [92] - Smoore has developed new technologies like FEELM Turbo and POWER ALPHA 2.0, maintaining its leadership in core vaporization technologies [92] New Business Opportunities Medical Vaporization - Smoore has developed the Air Smooth medical mesh nebulizer system, which reduces drug waste by 60% [166] - The global pulmonary drug delivery device market is expected to grow from $60.1 billion in 2023 to $99.5 billion by 2031 [166] Beauty Vaporization - Smoore has launched its own beauty vaporization brand, MOYAL, targeting the mid-to-high-end market [165] Special Vaporization - Smoore's CCELL ceramic core technology has gained significant market share in the US special vaporization market [164]